AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03875690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection of sodium chloride
Description: patients in the placebo group will receive 50 mL of sodium chloride 0.9% in a ready-to-use bag during 30 minutes at anaesthesic induction.
Study NCT03875690 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood samples
Description: electrolyte panel and glycemia performed within the first 24 hours after surgery.
Study NCT03875690 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: electrolyte panel and glycemia performed within the first 24 hours after surgery.
Study NCT01854437 — intervention group
Intervention type: DRUG
Intervention: Mg Oxide
Description: 250 mg orally for 4 weeks
Study NCT02460887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
Study NCT02460887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
Study NCT02460887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Active Comparator arm: Patients receive weekly cisplatin 40 mg/m² up to 7cycles during IMRT.
Study NCT02460887 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated Radiotherapy
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
Study NCT02460887 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated Radiotherapy
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
Study NCT03005249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neural stem cells therapy group
Description: The patients will be assigned to neural stem cells therapy group for cerebral palsy.
Study NCT03005249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the control group
Description: The patients will be assigned to the control group for cerebral palsy.
Study NCT00009958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-CEA(6D)/TRICOM vaccine
Description: Given SC
Study NCT00009958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-CEA(6D)-TRICOM vaccine
Description: Given intradermally
Study NCT00009958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study NCT00009958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01781910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acid drink supplement
Study NCT01781910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03655483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-010
Description: Full-human anti-pd-1 monoclonal antibodies
Study NCT01892189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063 Placebo
Description: TAK-063 placebo-matching tablets
Study NCT02050399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise
Description: The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
Study NCT02050399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isometric exercise
Description: The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
Study NCT02457793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
Study NCT02457793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0994
Description: GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
Study NCT04907955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification with implantation of presbyopia correcting IOL
Description: cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL
Study NCT01987999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acetogenins
Study NCT02463435 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional intervention
Description: Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
Study NCT02463435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention plus olive oil
Description: Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
Study NCT02463435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
Study NCT04556006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The data collection process of the study was carried out in two stages using data collection tools.~First stage: Personal Information Form and Compliance Questionnaire were applied to all patients in both groups. After anthropometric measurements, Framingham Risk Score was determined. The data collection forms were filled with the patients using face-to-face interview technique. The data collection process lasted for approximately 10-15 minutes. After the data collection, the patients in the intervention group were trained. No training was given to the patients in the control group but they received a Coronary Artery Disease Management Guide.~Second stage: 12 weeks after the first interview, the patients were interviewed again face-to-face interview technique and the forms and measurements applied initially were repeated.
Study NCT01712373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginseng
Description: it is kind of drug
Study NCT01712373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: it is placebo
Study NCT01950494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fiteBac Hand Sanitizer
Description: Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
Study NCT01950494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fiteBac Hand Sanitizer
Description: Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
Study NCT00749060 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: with our without brace
Study NCT00749060 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: kyphoplasty with balloons
Description: Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
Study NCT00749060 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: vertebroplasty
Description: Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
Study NCT00853346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
Study NCT00853346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: 12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
Study NCT00966771 — intervention group
Intervention type: DRUG
Intervention: Copper T380 IUD
Description: copper T 380 IUD
Study NCT00966771 — intervention group
Intervention type: DRUG
Intervention: Oral levonorgestrel
Description: 1.5 mg
Study NCT02656914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irlanda-2-Association
Description: Take 10 mL every 12 hours (2x/day), oral route.
Study NCT02656914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 10 mL every 12 hours (2x/day), oral route.
Study NCT02394483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 safety
Description: Safety assessments
Study NCT02394483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 tolerability
Description: Tolerability assessments
Study NCT02394483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318 pharmacokinetics
Description: Pharmacokinetic assessments
Study NCT02887534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1401-low dose
Description: SPARC1401- low dose
Study NCT02887534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1401-mid dose
Description: SPARC1401- mid dose
Study NCT02887534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1401-high dose
Description: SPARC1401-high dose
Study NCT02887534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference1401 (Tizanidine)
Description: Reference1401 (Tizanidine) three times a day
Study NCT02887534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo1401
Description: Placebo
Study NCT02887534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo1401
Description: Placebo
Study NCT02824380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4001 H
Description: 5% minoxidil / high dose of finasteride
Study NCT02824380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-4001 L
Description: 5% minoxidil / low dose of finasteride
Study NCT03013777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week CBT Program
Study NCT02973581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
Study NCT02973581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metamizol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
Study NCT02446457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02446457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02446457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02446457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04503421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Therapy
Description: Use of a tourniquet set to 50% of limb occlusion pressure while performing post operative physical therapy
Study NCT00636337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training
Description: Computer program training for attention difficulties.
Study NCT00636337 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison computer program
Study NCT02394483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo safety
Description: Safety assessments
Study NCT02973581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
Study NCT03627468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofpironium Bromide Gel, 5%
Description: Sofpironium Bromide Gel, 5%
Study NCT03627468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofpironium Bromide Gel, 15%
Description: Sofpironium Bromide Gel, 15%
Study NCT02973581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
Study NCT02973581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
Study NCT02973581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0,5 % bupivacaine with of 2% lidocaine
Description: in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
Study NCT02973581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proxymetacaine
Description: in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
Study NCT02973581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proxymetacaine
Description: in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
Study NCT01257581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: creatine
Description: creatine monohydrate powder
Study NCT01257581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: Tamoxifen citrate capsules
Study NCT01094262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone CR (standard pain medication)
Description: Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
Study NCT01094262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
Study NCT01094262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
Study NCT01094262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
Study NCT06076941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Before the training was given to the pregnant women in the experimental group who agreed to participate in the study, the Introductory Information Form, the Form for Assessing Pregnant Women's Behaviors Towards Oral and Dental Health, and the Form for Assessing Pregnant Women's Knowledge Levels Towards Oral and Dental Health were applied by face-to-face interview method. The application of the forms took 20-30 minutes. Then, a training time was planned on a suitable date for the pregnant women.~In order to ensure the effectiveness of the training, to answer the questions of the pregnant women effectively and to be able to direct them to the dentist in line with their needs, the training was applied in groups of maximum five people. Lecture, question and answer and demonstration methods were used in the training.~One month after the training, the necessary forms were applied to the pregnant women and the study was terminated.
Study NCT02389595 — intervention group
Intervention type: OTHER
Intervention: HIV positive subjects
Description: This group will provide a blood sample.
Study NCT02389595 — intervention group
Intervention type: OTHER
Intervention: Non-infected control subjects
Description: This group will be de-identified blood samples from a commercial source.
Study NCT00964353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
Study NCT00964353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
Study NCT04149535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinel® Cerebral Protection System
Description: cerebral embolic protection system
Study NCT02682550 — intervention group
Intervention type: PROCEDURE
Intervention: blood drawing
Description: blood drawing
Study NCT01737255 — intervention group
Intervention type: OTHER
Intervention: Whole body MRI
Description: Individuals will undergo whole body and brain MRI
Study NCT02394483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tolerability
Description: Placebo tolerability
Study NCT02394483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pharmacokinetics
Description: Plaacebo pharmacokinetics
Study NCT03331250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
Study NCT02635763 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femoral nerve and the lateral cutaneous nerve block
Description: Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
Study NCT02635763 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar plexus and sacral plexus nerve block
Description: Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
Study NCT00502944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselor-based HIV screening
Description: Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
Study NCT00502944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emergency staff member-based HIV screening
Description: Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
Study NCT00417118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saredutant
Description: oral administration (capsules)
Study NCT00417118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: oral administration (capsules)
Study NCT00417118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration (capsules)
Study NCT01736124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized cognitive training
Description: A variety of computer games tailored to address their personal cognitive deficits.
Study NCT01736124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control games
Description: A variety of computer games that are engaging but not designed to enhance cognitive skills
Study NCT03553927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low Energy Diet
Description: Caloric restriction to achieve weight loss